Episode

Groundbreaking Gene Therapy Restores Natural Hearing for Genetic Deafness

Podcast
Advances in Care
Published
Jul 23, 2026
Duration seconds
1108
Processing state
not_requested
Canonical source
https://advances-in-care.simplecast.com/episodes/groundbreaking-gene-therapy-restores-natural-hearing-for-genetic-deafness-2pO2fnh0
Audio
https://p.podderapp.com/1440337256/cdn.simplecast.com/media/audio/transcoded/20f5dff1-c9dc-44ab-8b84-fc16c4ca51b2/cc9697ff-ec07-4499-8331-0e85c7cccb15/episodes/audio/group/fb607ccf-0592-4b62-8487-8fc6e5abfa48/group-item/33ae0502-2fbf-4f44-9517-9403f7ac13b1/128_default_tc.mp3?aid=rss_feed&feed=TZu4B0z0
JSON
/v1/public/podcasts/advances-in-care-6039100/episodes/groundbreaking-gene-therapy-restores-natural-hearing-for-genetic-deafness
Markdown
/podcast/advances-in-care-6039100/groundbreaking-gene-therapy-restores-natural-hearing-for-genetic-deafness.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/advances-in-care-6039100/episodes/groundbreaking-gene-therapy-restores-natural-hearing-for-genetic-deafness/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/advances-in-care-6039100/groundbreaking-gene-therapy-restores-natural-hearing-for-genetic-deafness.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

On this episode of Advances in Care, Erin Welsh is joined by Dr. Lawrence Lustig, otolaryngologist-in-chief at NewYork-Presbyterian and Columbia. Dr. Lustig has spent decades working to advance various interventions to treat genetic hearing loss and after years of research his team was the first to show that gene therapies could be effective at reversing genetic hearing loss in mouse models and eventually, humans. In April 2026, the FDA approved the first ever gene therapy for a rare form of genetic otoferlin deafness based on the work pushed forward by Dr. Lustig. Dr. Lustig shares how he and his team brought this approach to treating genetic deafness from mouse models, to humans, to FDA approval in record time, and why this new therapy will have a profound effect on treatments for hearing loss in the years to come.